Sign in
WithdrawnNo phase

Transanal Versus Laparoscopic Total Mesorectal Excision for Rectal Cancer

Key facts

Who runs it
Ruijin Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Withdrawn
Started
Jun 2019
Ended
Mar 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Transanal total mesorectal excision
  • Laparoscopic total mesorectal excision
Record updated
17 February 2020
Why it stopped
No funding was raised

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • 18 years < age < 80 years
  • Body mass index (BMI) <30 kg/m2
  • Tumor located in mid and low rectum ( the lower border of the tumor is located distal to the peritoneal reflection)
  • Pathological rectal carcinoma
  • Clinically diagnosed cT1-3N0-2 M0 lesions according to the 7th Edition of AJCC Cancer Staging Manual with or without neoadjuvant therapeutic history
  • Tumor size of 5 cm or less
  • ECOG score is 0-1
  • ASA score is Ⅰ-Ⅲ
  • Informed consent

Who cannot take part

  • Intolerance of surgery for severe comorbidities
  • Previous abdominal surgery
  • History of inflammatory bowel disease
  • Severe mental disease
  • Emergency operation due to complication (bleeding, perforation or obstruction) caused by rectal cancer
  • Requirement of simultaneous surgery for other disease
  • Requiring a Mile's procedure
  • Fecal incontinence
  • Pregnant woman or lactating woman

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study is designed to evaluate the short-term and long-term results after transanal total mesorectal excision (TaTME) for the resection of mid and low rectal cancer compared with laparoscopic total mesorectal excision(LaTME).

The 2 groups in the trial

  • TaTMETreatment being tested

    Patients with mid or low rectal cancer undergo transanal total mesorectal excision.(assisted by laparoscopy to control the IMA)

    Treatment: Transanal total mesorectal excision

  • LaTMEExisting treatment, for comparison

    Patients with mid or low rectal cancer undergo laparoscopic total mesorectal excision.

    Treatment: Laparoscopic total mesorectal excision

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Single-center Prospective Randomized Controlled Study of the Transanal Total Mesorectal Excision Versus Laparoscopic Total Mesorectal Excision in Rectal Cancer
Record updated
17 February 2020